Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background: Angioimmunoblastic T-cell lymphoma (AITL) is a distinct subtype of peripheral T-cell lymphoma (PTCL) and accounts for 2% of all non-Hodgkin lymphomas. Its typical characteristics include an aggressive course, progressive lymphadenopathy, hepatosplenomegaly, systemic symptoms, anemia, hypergammaglobulinemia, and generally poor prognosis.
Methods: We describe a rare case in which the left inguinal lymph node was completely excised and biopsied one year ago.
Clinical, Pathologic, and Molecular spectrum of Angioinmmunoblastic T-cell Lymphoma Cutaneous Lesions: Clinical, Pathologic, and Molecular Analysis.
Am J Surg Pathol
January 2025
Department of Pathology, Health Research Institute-Fundación Jímenez Diaz University Hospital. Universidad Autónoma de Madrid (IIS-FJD, UAM).
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive malignancy that frequently presents with extranodal involvement. Cutaneous tropism is clinically and histopathologically variable, which may pose a diagnostic challenge. We conducted a retrospective analysis of 40 samples of 20 cases of cutaneous AITL, focusing on the clinicopathologic and molecular correlations between skin and lymph node (LN) samples.
View Article and Find Full Text PDFAngioimmunoblastic T-cell lymphoma harboring a t(8;14)(q24;q11.2)/TCR::MYC translocation that presented with intestinal infiltration.
Ann Hematol
December 2024
Department of Hematology, Tohoku University Hospital, Sendai, Japan.
Although rearrangement of the MYC oncogene (MYC-R) is frequently observed in aggressive B-cell lymphomas, it is extremely rare in T-cell malignancies. A 64-year-old man who had been under observation for several years because of asymptomatic pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALToma) was admitted to our hospital because of poor general condition and hypotension. Blood tests revealed thrombocytopenia and elevated serum lactate dehydrogenase levels, whereas computed tomography revealed systemic lymphadenopathy and splenomegaly.
View Article and Find Full Text PDFRecent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era.
Leuk Res
January 2025
Laboratory of Hemato-Immunology, Graduate School of Health Sciences, University of the Ryukyus, Nishihara, Japan.
Article Synopsis
- Adult T-cell leukemia/lymphoma (ATLL) is a type of cancer linked to HTLV-1 virus infection, with the WHO's new 5th Edition classification outlining essential and desirable diagnostic criteria for its identification.
- A new diagnostic method combining HBZ-ISH and tax-PCR enhances detection of HTLV-1 in cases where only preserved tissue samples are available, alongside traditional Southern blot techniques.
- The review addresses the morphological and phenotypic characteristics of ATLL, noting the prevalence of certain phenotypes, genetic abnormalities, and emphasizing the need for further research and classification in understanding the disease's complex nature.
Sustained yet non-curative response to lenalidomide in relapsed angioimmunoblastic T-cell lymphoma with acquired chidamide resistance: a case report with 10-year follow-up, genetic insights and literature review.
Front Oncol
November 2024
Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China.
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive subtype of peripheral T-cell lymphoma (PTCL) characterized by its T-follicular helper (TFH) phenotype. Relapsed and refractory disease is common in AITL and often associated with a poor prognosis. The presence of epigenetic abnormalities, immune dysregulation, hyperinflammation and active angiogenesis in AITL offers potential targets for histone deacetylase (HDAC) inhibitors and immunomodulatory drugs (IMiDs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!